For the quarter ending 2025-12-31, INM had -$2,376,243 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | -2,028,223 | -1,726,899 | -8,162,133 |
| Amortization and depreciation | 53,201 | 53,202 | 212,839 |
| Share-based compensation | 25,264 | 20,205 | 119,307 |
| Amortization of right-of-use assets | 104,818 | 103,478 | 321,885 |
| Inventory write-down | 70,000 | - | - |
| Interest income received on short-term investments | -774 | - | -34 |
| Unrealized foreign exchange loss | - | - | 75,928 |
| Credit losses | - | - | 2,424 |
| Unrealized foreign exchange loss | -1,892 | -1,358 | - |
| Inventories | 127,091 | -70,366 | -283,151 |
| Prepaids and other currents assets | 467,042 | -129,992 | -173,980 |
| Accounts receivable | -159,977 | -122,160 | 114,690 |
| Accounts payable and accrued liabilities | -58,348 | -274,066 | -249,728 |
| Lease obligations | -109,917 | -107,412 | -429,880 |
| Total cash used in operating activities | -2,376,243 | -1,607,616 | -7,766,951 |
| Proceeds from the private placement | - | - | 8,130,299 |
| Proceeds from the sale of pre-funded warrants | - | - | 5,024,891 |
| Share issuance costs | 0 | 137,178 | 883,978 |
| Total cash (used in) provided by financing activities | 0 | -137,178 | 12,271,212 |
| Decrease in cash and cash equivalents during the period | -2,376,243 | -1,744,794 | 4,504,261 |
| Effect of exchange rate changes on cash | - | - | 0 |
| Cash and cash equivalents at beginning of period | 9,331,077 | 11,075,871 | 6,571,610 |
| Cash and cash equivalents at end of period | 6,954,834 | 9,331,077 | 11,075,871 |
InMed Pharmaceuticals Inc. (INM)
InMed Pharmaceuticals Inc. (INM)